OFOlga V. Fedorishina

Olga V. Fedorishina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga V. Fedorishina has a total of 674 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in the level and intra-visit variability of office blood pressure under non-standard measurement conditions in patients with hypertension

    by K. V. Protasov, O. V. Fedorishina, S. N. Galsanova, T. A. Karpova, Светлана Жамсарановна Сампилова

    Objective . The aim of the study was to assess the dynamics of office blood pressure (BP) levels and to analyse factors associated with the individual variability in BP changes under different measurement conditions in patients with hypertension (HTN). Design and methods . The study enrolled 200 outpatients with confirmed HTN, including 80 men. The median age was 68,0 (58–73) years. BP was measured using an automated oscillometric device according to the standard protocol (the reference BP), followed by a series of single measurements conducted under conditions simulating common protocol violations: the absence of back support, crossed legs, a mismatch between BP cuff size and arm circumference, the patient talking during the procedure, and preceding physical activity. The frequency of uncontrolled HTN (defined as systolic BP (SBP) ≥ 140 mmHg and/or diastolic BP (DBP) ≥ 90 mmHg) was assessed. For each participant, the absolute and percentage (PV) deviations from the reference BP were calculated, along with the individual BP variability (SDPV), defined as the standard deviation of PV across the different measurement conditions. Patients in the upper quartile of SDPV were classified as having high intra-visit BP variability. Predictors of high BP variability were identified using logistic regression and receiver operating characteristic (ROC) analysis. Results . All non-standard measurement conditions, except for the use of an oversized BP cuff, resulted in a significant increase in BP compared with the reference values. The greatest increase was observed in the seated position with crossed legs, with an average rise of 13,5 mmHg in SBP and 3,0 mmHg in DBP. The proportion of patients classified as having uncontrolled HTN rose from 19 % (based on the reference BP) to 58,5 % under the crossed-legs condition. After adjustment of the regression model for sex, age, and body weight, high SBP changes variability (SDPV ≥ 9,0 %) was independently associated with a reference SBP < 122 mmHg (odds ratio [OR] 4,01; 95 % confidence interval [CI] 2,02–7,93) and a history of an acute cerebrovascular event (OR 2,55; 95 % CI 1,14–5,72). High DBP changes variability (SDPV ≥ 7,1 %) was independently associated with a reference DBP < 73 mmHg (OR 2,86; 95 % CI 1,49–5,50). Conclusions . Non-adherence to the recommended BP measurement protocol predominantly leads to increased BP readings and contributes to the overdiagnosis of uncontrolled HTN. High intra-visit BP variability in response to altered measurement conditions is associated with a history of acute cerebrovascular events and lower reference BP levels. These findings underscore the critical importance of strict adherence to the established BP measurement protocol.


  • Open Access

    Inappropriate sinus tachycardia presented during pregnancy (clinical case)

    by E. S. Eniseeva, K. V. Protasov, O. V. Fedorishina, T. P. Vlasyuk, N. A. Khramtsova

    Inappropriat e sinus tachycardia (IST) is a sinus tachycardia unexplained by visible physiological and secondary causes with a resting heart rate of more than 100 beats per minute. The true prevalence of IST is unknown. At the same time, IST seems to be common in normal pregnancies, which causes significant difficulties in differential diagnosis and patient management. There is no practice of diagnosing IST in Russia. An analysis of the literature revealed no descriptions of clinical cases of IST in pregnant women in Russian publications and found only one report of IST in the review article. The paper presents a clinical case of IST in a 33-year-old woman in the third trimester of pregnancy. The patient had sinus tachycardia with a heart rate of 180 beats per minute, accompanied by complaints of shortness of breath, weakness, and palpitations. During Holter monitoring, sinus tachycardia was recorded during both daytime and nighttime hours. A differential diagnosis with paroxysmal reciprocal sinus tachycardia and postural orthostatic tachycardia syndrome was performed. Other potential causes of sinus tachycardia were ruled out. The diagnosis of HCT has been established. Therapeutic options were limited due to pregnancy. Administration of metoprolol succinate at a dose of 25 mg produced only a modest reduction in heart rate to 120 beats per minute. At 38 weeks of gestation, delivery was performed via cesarean section. During dynamic follow-up 4 months after delivery, a decrease in tachycardia to 100 beats per minute was noted, which requires continued monitoring. The features of the presented clinical case are the extremely high heart rate for the sinus rhythm described for the first time (180 beats per minute) and persistent moderate sinus tachycardia 4 months after delivery.

  • Open Access

    Current hypertension treatment possibilities and tactics in patients with comorbidities. The role of selective imidazoline receptor agonists. Expert opinion

    by T. V. Pecherina, G. A. Chumakova, Yu. I. Grinshtein, O. Yu. Donirova, N. V. Zakharchuk, V. V. Kashtalap, T. A. Petrichko, L. I. Syromyatnikova, O. V. Fedorishina, S. М. Cherepenin, et al.

    Hypertension (HTN) is a serious public health problem. Despite advances in diagnosis and public awareness, the percentage of controlled cases remains low, especially among men and the elderly. The main challenges are related to comorbidities such as obesity, diabetes, chronic kidney disease, and obstructive sleep apnea, which worsen the prognosis and increase the risk of cardiovascular events. The approach to HTN treatment should be individualized and take into account specific disease phenotypes and comorbidities. It is important to identify patients with increased sympathetic nervous system activity, as this group experiences the greatest difficulties in blood pressure control. Moxonidine, a centrally acting agent, selectively stimulates imidazoline receptors in the brain, causing a decrease in sympathetic activity and effective reduction in blood pressure. The need for a personalized approach to HTN therapy is driven by the growing number of patients with multiple comorbidities and complex pathogenesis. New approaches, including early initiation of combination therapy and targeted management of metabolic risk factors, will reduce cardiovascular morbidity and mortality. Moxonidine plays a key role within antihypertensive medications due to its unique mechanism of action and ability to positively impact a wide range of HTN-related pathologies

  • Open Access

    Treatment of hypertensive patients in Russian real-world practice based on the data from 2025 blood pressure measurement campaign

    by O Rotar, E Moguchaya, M Boyarinova, O Rubanenko, E Gubareva, O Gaberman, N Shimokhina, S Shtarik, L Danilova, A Evsyukov, et al.

    Aim. To evaluate the features of antihypertensive therapy (AHT), adherence to therapy and achievement of target blood pressure (BP) in patients with hypertension (HTN) in Russian real-world practice after the implementation of 2024 Russian clinical guidelines on hypertension in adults.Material and methods. During May 2025, 7990 patients with HTN from 19 Russian cities and Tiraspol (Pridnestrovian Moldavian Republic) took part in the BP measurement campaign. Outpatients with HTN over the age of 18 voluntarily participated in the campaign. During the screening, BP and pulse were measured three times using an automatic or mechanical BP monitor. In addition, a questionnaire was filled out on behavioral risk factors, BP self-monitoring skills, medication adherence, AHT, comorbidities and related therapy. The effectiveness of AHT was understood as achieving the target BP level Results. The analysis included 7972 respondents aged 18 to 96 years (median age 62 years [51;71]), including 3372 men (42,3%). Among the participants, 74,4% took AHT, while 62,6% achieved target BP Conclusion. In outpatient practice after the implementation of 2024 Russian clinical guidelines for HTN, an increase in the coverage and efficacy of AHT, and the HTN control is observed compared to the population data of 2020-2022. AHT prescription profile indicates a decrease in the share of monotherapy and an increase in the share of triple combination. The use of single-pill antihypertensive combinations is growing, but remains insufficient. The results obtained demonstrate the importance of discussing with a physician the need to comply with recommendations in hypertensive patients to improve adherence and treatment effectiveness.


  • Open Access

    Daily blood pressure profile by adding spironolactone to standard two- component antihypertensive therapy

    by A. M. Torunova, O. V. Fedorishina, I. V. Reshina, K. V. Protasov

       Aim of research: to evaluate the dynamics of ambulatory blood pressure monitoring parameters in patients with arterial hypertension by adding spironolactone to standard antihypertensive therapy of calcium antagonist and angiotensin-converting enzyme inhibitor antihypertensive therapy.   Materials and methods. 70 patients were randomized into two groups: the first group received of amlodipine/lisinopril combination, the second group followed the same regimen of therapy with addition of 25 mg/day of spironolactone. The monitoring period was 6 months. In all patients we studied and compared the dynamics of office blood pressure, ambulatory blood pressure monitoring parameters including morning blood pressure surge and morning blood pressure surge rate initially, through/peak ratio.   Results. After of 24 weeks of treatment the office and daily average blood pressure decreased in both groups. Diastolic blood pressure decreased to a greater extent in the spironolactone supplementation group. In the spironolactone group, in distinction from the two-component therapy group, the morning blood pressure surge decreased on average by of 5,0 (-15,4; +2,4) mm Hg. In the standard therapy group, an increase in the morning blood pressure surge rate on average by of 3,1 (1,3; +16,4) mm Hg/h was noted, which was not observed in the spironolactone group. The mean final effect/peak effect ratio for systolic blood pressure became equal 43,5 (7,5; 71,0) % during two-component therapy and 69,0 (46; 89) % in the spironolactone group (p < 0,05).   Conclusions: The addition of spironolactone to the standard two-component combination in patients with arterial hypertension leads to an additional decrease in office and average daily diastolic blood pressure, reduction of morning blood pressure rise and increase of the antihypertensive effect uniformity in the form of an increase in the final effect/peak effect ratio.

  • Open Access

    Impact of vaccination status on the clinical course and outcomes of acute COVID-19 period: data from the international registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV-4)

    by G Arutyunov, E Tarlovskaya, A Arutyunov, D Polyakov, Yu. Lopatin, A Chesnikova, L Balykova, A Vaisberg, A Galyavich, N Grigorieva, et al.

    Aim. To assess the effectiveness of vaccination against Omicron and Delta variants according to the international registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV-4).Material and methods. The AKTIV-4 registry included men and women over 18 years of age with a diagnosis of coronavirus disease 2019 (COVID-19) (oropharyngeal and nasopharyngeal swabs, SARS-CoV-2 antibody titers, typical computed tomography performance), undergoing hospital treatment. A total of 3543 patients from 25 medical centers in 7 countries (the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan) were included in the AKTIV-4 registry.Results. The clinical status of patients from the AKTIV-4 registry was more severe than in the AKTIV-1 and AKTIV-2 registries. Patients in the AKTIV-4 registry were older than patients in the AKTIV-1 registry. The inhospital mortality rate in patients in the AKTIV-4 registry was higher (8,41%, pConclusion. Vaccination, primarily with Sputnik V, is an independent predictor of survival in hospitalized COVID-19 patients and reduces the risk of death by 62% according to multivariate analysis.

  • Open Access

    2023 All-Russian screening for hypertension: results

    by О. П. Ротарь, I. N. Ilyanova, M. A. Boyarinova, E. V. Moguchaya, K. M. Tolkunova, V. A. Dyachkov, O. A. Rubanenko, A. O. Rubanenko, O. E. Gaberman, E. Yu. Gubareva, et al.

    Aim. To assess awareness of blood pressure (BP) level, adherence to therapy and achievement of target BP in residents of Russian regions as part of the 2023 hypertension (HTN) screening campaign.Material and methods. During May 2023, 4613 participants from 23 cities of Russia took part in the screening. Participation was voluntary without restrictions on sex. All patients aged over 18 years. During screening, BP and pulse were measured three times using automatic or mechanical BP monitors, and a questionnaire about behavioral risk factors, concomitant diseases and therapy was filled out. HTN was diagnosed with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or taking antihypertensive therapy (AHT).Results. The analysis included data from 4585 respondents aged 18 to 95 years with an average age of 45 [28;59] years, of which 1729 were men (37,7%). The proportion of hypertensive patients was 49,6%. Among them, 62,8% took AHT and achieved target BP in 76,6% and 45,7% with the target BP criterion Conclusion. The data obtained indicate, on the one hand, a continuing insufficient level of awareness about high BP and the use of antihypertensive drugs among the population, but there is a tendency to improve the effectiveness of the treatment of hypertension, including the use of fixed-dose combinations of antihypertensive drugs.


  • Open Access

    Newly diagnosed diseases and the frequency of their occurrence in patients after a new coronavirus infection. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

    by G P Arutyunov, E I Tarlovskaya, A G Arutyunov, D S Polyakov, Yu. N Belenkov, A O Konradi, Yu. M Lopatin, A P Rebrov, S N Tereshchenko, A I Chesnikova, et al.

    Aim. To analyze newly diagnosed diseases and features of the post-COVID course in patients after a coronavirus disease 2019 (COVID-19) within 12-month follow-up.Material and methods. A total of 9364 consecutively hospitalized patients were included in the ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to the ACTIV registry, 18,1% of patients after COVID-19 had newly diagnosed diseases (NDDs) over the next 12 months. Hypertension (HTN), type 2 diabetes and coronary artery disease (CAD) prevailed in the NDD structure. Comparison of the age-standardized incidence of NDDs (HTN, CAD, diabetes) in the post-COVID period in the ACTIV registry with NDD incidence in 2019 according to Rosstat and the expected incidence of NDDs according to the EPOHA study revealed that HTN, diabetes, CAD in patients after COVID-19 were registered more often as follows: HTN by 7,0 and 4,4 times, diabetes by 7,3 and 8,8 times, CAD by 2,3 and 2,9 times, respectively. NDDs most often developed in patients aged 47 to 70 years. Comparison of the actual and expected number of cases of newly diagnosed HTN, CAD and diabetes depending on age showed that the actual number of cases in the population of patients in the ACTIV register is significantly higher than expected for patients aged 45-69 years and for patients with hypertension or diabetes and aged Conclusion. Available evidence suggests that a strategy for managing COVID-19 survivors should include mandatory screening for early detection of cardiovascular disease and diabetes, which will be key to reducing the risk of further COVID-19 consequences.


  • Open Access

    The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries

    by A G Arutyunov, E I Tarlovskaya, G R Galstyan, T I Batluk, R A Bashkinov, G G Arutyunov, Yu N Belenkov, A O Konradi, Yu M Lopatin, A P Rebrov, et al.

    BACKGROUND. There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).AIM. To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.MATERIALS AND METHODS. AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected the data of hospitalized patients and included 3 visits. All subjects were divided into 3 groups: not overweight (n=2139), overweight (n=2931) and obese (n=2666).RESULTS. A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (pCONCLUSION. Overweight and/or obesity is a significant risk factor for severe course of the new coronavirus infection and the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.


  • Open Access

    Clinical features of post-COVID period. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

    by G. P. Arutyunov, E. I Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, et al.

    Aim. To investigate on post-COVID period in patients of the Eurasian region.Material and methods. A total of 9364 consecutively hospitalized patients were included in ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to ACTIV register, 63% of patients after COVID-19 had new adverse symptoms or exacerbations of the existing symptoms lasting for up to 1 year. After hospital discharge, 79,8% of patients sought unscheduled medical attention in the first 3 months, 79,1% at 4-6 months, and 64,8% at 7-12 months. Readmission rate was 11,8% in the first 3 months, 10,9% at 4-6 months, and 10,1% at 7-12 months. The most common reasons for unscheduled treatment in the first 3 months were uncontrolled hypertension, decompensated type 2 diabetes, destabilization of coronary artery disease, gastrointestinal disease, AF episodes, exacerbation of asthma and chronic obstructive pulmonary disease, decompensated heart failure (HF). The 12-month mortality of COVID-19 survivors after the discharge was 3,08%. Multivariate analysis showed that independent risk factors for fatal outcome were age (direct correlation), the levels of hemoglobin (inverse correlation), oxygen saturation (inverse correlation), and aspartate aminotransferase (direct correlation), as well as class III-IV HF, prior stroke, cancer, inhospital acute kidney injury. Based on these identified risk factors, a nomogram was constructed to determine the 3-month mortality risk after discharge.Conclusion. Analysis of ACTIV register showed that end of the acute phase of COVID-19 does not imply a complete recovery.